Abstract:Since the advent of the twentieth century, several severe virus outbreaks have occurred—H1N1 (1918), H2N2 (1957), H3N2 (1968), H1N1 (2009) and recently COVID-19 (2019)—all of which have posed serious challenges to public health. Therefore, rapid identification of efficacious antiviral medications is of ongoing paramount importance in combating such outbreaks. Due to the long cycle of drug development, not only in the development of a “safe” medication but also in mandated and extensive (pre)clinical trials before a drug can be safely licensed for use, it is difficult to access effective and safe novel antivirals. This is of particular importance in addressing infectious disease in appropriately short period of time to limit stress to ever more interlinked societal infrastructures; including interruptions to economic activity, supply routes as well as the immediate impact on health care. Screening approved drugs or drug candidates for antiviral activity to address emergent diseases (i.e. repurposing) provides an elegant and effective strategy to circumvent this problem. As such treatments (in the main) have already received approval for their use in humans, many of their limitations and contraindications are well known, although efficacy against new diseases must be shown in appropriate laboratory trials and clinical studies. A clear in this approach in the case of antivirals is the “relative” simplicity and a high degree of conservation of the molecular mechanisms that support viral replication—which improves the chances for a functional antiviral to inhibit replication in a related viral species. However, recent experiences have shown that while repurposing has the potential to identify such cases, great care must be taken to ensure a rigourous scientific underpinning for repurposing proposals. Here, we present a brief explanation of drug repurposing and its approaches, followed by an overview of recent viral outbreaks and associated drug development. We show how drug repurposing and combination approaches have been used in viral infectious diseases, highlighting successful cases. Special emphasis has been placed on the recent COVID-19 outbreak, and its molecular mechanisms and the role repurposing can/has play(ed) in the discovery of a treatment.

Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases

Drug Repurposing Techniques in Viral Diseases

The urgent need for pan-antiviral agents: from multitarget discovery to multiscale design

Antivirals with common targets against highly pathogenic viruses

Addressing the Threat of Emerging Viral Infections

Emerging viruses and current strategies for vaccine intervention

Anno 2021: Which antivirals for the coming decade?

Revolutionizing Antiviral Therapeutics: In Silico Approaches for Emerging and Neglected RNA Viruses

New perspective of small-molecule antiviral drugs development for RNA viruses

Lessons learnt from broad-spectrum coronavirus antiviral drug discovery

Computational repurposing of drugs for viral diseases and current and future pandemics

Medicinal chemistry strategies toward broad-spectrum antiviral agents to prevent next pandemics

Combating Emerging Respiratory Viruses: Lessons and Future Antiviral Strategies

Pandemic preparedness: On the efficacy of non‐pharmaceutical interventions in COVID‐19 and about approaches to predict future pandemic viruses

Editorial: Antiviral options for emerging and reemerging viral diseases: current therapeutics, novel drug candidates and new approaches

Search, Identification, and Design of Effective Antiviral Drugs Against Pandemic Human Coronaviruses

Biosimilars as antivirals: opportunities and challenges

Broad-spectrum antiviral inhibitors targeting pandemic potential RNA viruses

In vivo expressed biologics for infectious disease prophylaxis: rapid delivery of DNA-based antiviral antibodies

Revolutionizing viral disease treatment: phase separation and lysosome/exosome targeting as new areas and new paradigms for antiviral drug research

Therapeutic strategies for COVID-19: progress and lessons learned